Who was studied?
43 screened patients; 39 received treatment and formed the reported response denominator.
What does the publication report?
ORR among 39 treated patients was 30.8%, with 4 complete and 8 partial responses. Median PFS was 4.2 months.
Safety findings
No grade ≥3 treatment-related adverse events were reported.
How should we interpret it?
Conference-level, non-randomized evidence. Linked reports may include the same participants and should not be counted as independent trials.
Read the original source
This independently written summary was checked against the publicly available abstract. Selected figures, where included, are checked against the full publication. This is not a full-paper translation or a clinical recommendation.
PRaG 5.0: Personalized thymosin alpha-1 and radioimmunotherapy for advanced refractory solid tumors—Data from an expanded cohort. · DOI: 10.1200/JCO.2026.44.16_suppl.2516
Related publications from the same research program
- Thymosin alpha-1–enhanced PRaG regimen: A novel approach to boosting immune dynamics and therapeutic efficacy in advanced solid tumors.
- A precise thymalfasin-regulated PRaG regimen for advanced refractory solid tumors: An open-label, prospective, multicenter clinical study (PRaG 5.0 study).
- Evaluation of the efficacy and safety of a precise thymalfasin-regulated PRaG regimen for advanced refractory solid tumours: protocol for the open-label, prospective, multicentre study (PRaG5.0 study)
Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.